ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
2024年7月24日 - 5:00PM
- Dosing of patients in new combination treatment arm –
IOS-1002 plus KEYTRUDA
Schlieren (Zurich Area), Switzerland – July 24,
2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using
its HLA-based technology platform to develop first-in-class and
innovative therapeutics for the treatment of cancer and autoimmune
diseases, today announced the expansion of its ongoing Phase
I clinical trial of IOS-1002 in combination with MSD (Merck &
Co., Inc., Rahway, NJ, USA)'s anti-PD-1 therapy, KEYTRUDA®
(pembrolizumab) for the treatment of advanced solid tumors.
This is a first-in-human, open-label,
non-randomized and multicenter trial designed to assess the safety
profile, determine the optimal dosing, and evaluate the anti-tumor
activity of IOS-1002 when used alone and in combination with
KEYTRUDA, an established immune checkpoint inhibitor.
“We are excited to open a new arm of our ongoing
Phase I clinical trial and combine IOS-1002 with KEYTRUDA, the
world’s leading PD1 inhibitor,” said Dr. Reinhard Ambros, CEO and
Executive Chairman of the Board of ImmunOs Therapeutics. “IOS-1002
has the potential to enhance the anti-tumor activity of KEYTRUDA,
offering a promising new treatment option for patients with
advanced solid tumors. This trial represents a significant
milestone in our mission to develop innovative therapies that
harness the power of the immune system to fight cancer.”
“The combination of IOS-1002 with KEYTRUDA
represents an innovative approach for cancer treatment, leveraging
the strengths of both therapies by targeting multiple inhibitory
checkpoint receptors,” said Stephen Luen, MD, Principal
Investigator of the study at the Peter MacCallum Cancer Center in
Melbourne, Australia. “We look forward to assessing the optimal
treatment for our patients with advanced-stage cancer who have
limited therapeutic options.”
IOS-1002 is a novel, multifunctional
immunotherapy agent for the treatment of advanced solid tumors that
simultaneously targets several immune checkpoints. It is based on a
naturally occurring human leukocyte antigen (HLA) targeting LILRB1
(ILT2), LILRB2 (ILT4), and KIR3DL1. Designed to activate both
innate and adaptive immune cells it modulates the tumor
microenvironment, potentially enhancing the effectiveness of
existing treatments like KEYTRUDA. By combining these two
therapies, ImmunOs Therapeutics aims to improve patient outcomes
and expand the therapeutic options for individuals battling
advanced solid tumors.
ImmunOs Therapeutics is committed to advancing
the clinical development of IOS-1002 and exploring its potential to
improve the lives of cancer patients. For more information, please
visit www.immunostherapeutics.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
###
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG leverages its HLA-based
technology platform to develop first-in-class therapeutics for the
treatment of cancer and autoimmune diseases. ImmunOs’ lead program
is a multi-functional HLA-fusion protein that binds specific LILRB
(leukocyte immunoglobulin-like) and KIR (killer cell
immunoglobulin-like) receptors and can stimulate both the innate
and the adaptive immune systems of cancer patients to eliminate
tumor cells. ImmunOs is also developing different modalities to
agonize receptors for the modulation of the immune system in
autoimmune diseases.
The Company is supported by leading
international investors including Pfizer Ventures, Gimv, Mission
BioCapital, BioMed Partners, Schroder Adveq, GL Capital, PEAK6, and
Fiscus. ImmunOs Therapeutics is located in Schlieren,
Switzerland.
Company ContactImmunOs Therapeutics AG Wagistrasse 188952
Schlieren (Zurich Area),
Switzerlandinfo@immunostherapeutics.com
Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth
Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64 /Tel. +49
30 23 63 27 68